Business Wire

In addition, Ivanti was named an outperformer in the report.

SALT LAKE CITY--(BUSINESS WIRE)-- Ivanti, the tech company that breaks down barriers between IT and security so that Everywhere Work can thrive, has been named a Leader and Outperformer in the 2024 GigaOm Radar for IT Asset Management (ITAM). GigaOm produces Radar reports to compare the most prominent vendors in a specific market and provides guidance to enterprises regarding how to evaluate and choose... (continue reading...)

DENVER--(BUSINESS WIRE)-- Civitas Resources, Inc. (NYSE: CIVI) (“Civitas” or the “Company”) announced today the pricing of an underwritten public offering of an aggregate of 6,956,520 shares of its common stock (the “Offering”) by an affiliate of Canada Pension Plan Investment Board (the “Selling Stockholder”) at a price to the public of $73.80 per share. Civitas is not selling any shares of common stock in the Offering and will not receive any... (continue reading...)

SINGAPORE--(BUSINESS WIRE)-- Reference is made to the stock exchange announcement made by BW LPG Limited ("BW LPG” or the "Company") on 3 May 2024 regarding the board of directors proposal to implement a scheme of arrangement (the "Scheme”) between the Company and its shareholders pursuant to Section 99 of the Bermuda Companies Act 1981 as amended in order to effect a discontinuance of the Company from Bermuda and continuance to Singapore.

On 15 May 2024 the... (continue reading...)

All dollar amounts expressed are in thousands of U.S. dollars unless otherwise indicated.

Q1 2024 and Other Highlights

• Revenues of $42.2 million in Q1 2024 vs. 57.4 million in Q1 2023; Lower revenues driven by a significant decrease in vanadium prices; Revenues per pound soldi of $6.91 in Q1 2024 vs. $9.14 in Q1 2023
• Operating costs of $49.7 million in Q1 2024 vs. $45.9 million in Q1 2023
• Cash operating costs excluding royalties per pound6 of $6.12 per lb... (continue reading...)

95.7% of patients responded to Breyanzi in the TRANSCEND FL trial

Breyanzi provided sustained clinical benefit with median duration of response not reached and the majority (77.1%) of responders in ongoing response at 18 months

Breyanzi is a personalized therapy with a differentiated profile, offering durable responses and a consistent safety profile across trials

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the U.S.... (continue reading...)